Cervical cancer library

Single-Dose HPV Vaccine Evaluation Consortium

Current published evidence for single-dose HPV vaccination

Consortium fact sheet

White paper

Technical synthesis

General summary

External resources

  • HPV World. Can we use one dose of HPV vaccine to ensure long term protection? September 2017, Year 1, No 23-31.
  • Vaccine. Preventing Cervical Cancer: How much HPV Vaccine do we need? August 2018, Volume 36, Issue 32, Part A, Pages 4759-4836.

Photo: PATH/Will Boase

Accumulating evidence suggests a single-dose of human papillomavirus (HPV) vaccine may elicit an immune response to protect against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.

Clinical trials, observational studies, and modeling analyses are currently being conducted to evaluate the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single-dose HPV vaccination. If demonstrated to be effective, single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs. For low- and lower-middle-income countries that have delayed introducing HPV vaccines because of financial, logistical or other barriers; a single-dose HPV vaccination schedule could accelerate introduction of HPV vaccines into national immunization schedules.

The Single-Dose HPV Vaccine Evaluation Consortium encompasses nine leading independent research institutions working together to collate and synthesize existing evidence and evaluate new data on the potential for single-dose HPV vaccination. The consortium’s goal is to evaluate this evidence over the course of the project (2018–2021) to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications.

Learn more through the resources at right.